BIRC5 and neoplasm: Our data are not inconsistent with the findings of other studies that identify high cytoplasmic expression of Survivin as a prognostic factor in therapeutically resistant tumours, as results here using the NB-500-201 antibody show that high levels of cytoplasmic Survivin are expressed in higher grade ependymomas and CPC.